“It will serve as a control tower for the development of the pharmaceutical-bio industry in Korea”
[베이비타임즈=유경수 기자] In preparation for the post-corona era, the Korea New Drug Development Research Association (CEO, Dong-Yeon Kim) organized the Secretariat on the 1st to support global open innovation, pharmaceutical and bio drug development and business expansion of member companies in preparation for the post-corona era. On the 24th, it was announced on the 24th that the organization was reorganized into a four-team system.
First, the R&D Promotion Headquarters (R&D Policy Planning Team, Business Development Team) is in charge of policy for the global growth of the pharmaceutical and biohealth industry, domestic and international industry, academia, research cooperation, open innovation, and industrial support. I took it. In addition, the business operation headquarters (Planning Budget Team, External Cooperation Team) is in charge of establishing and managing the union’s budget plan, public relations with the press, and overseeing cooperation with the government and related organizations, and Jaecheon Yeo (Secretary General) serves as the key control tower as the head of the headquarters. .
This time, it is evaluated that the Korea New Drug Development Research Association has established an organization suitable for the leadership in the development of biohealth, pharmaceuticals, and new bio drugs, which are one of the nation’s big three industries in name and reality. In addition, this reorganization focuses on new drug-related businesses not only domestically, but also overseas, so it is evaluated that it has attempted a change to become a global institution.
Currently, the affiliates of the Korea New Drug Development Research Association include the Pharmaceutical Industry Technology Exchange Center (PTBC) and the Innovation Policy Research Center (InnoPol). There is a research group (K-BD Group).
In addition, subsidiary committees include the Pharmaceutical Industry Technology Exchange Center Technology Transaction Committee, Interbiz Bio Partnering & Investment Forum Organizing Committee, R&D-oriented high-quality pharmaceutical and bio-company IR Committee, and the Pharmaceutical and Bio-Health Industry Technology Management Committee. . In addition, as an affiliated research project group, a biotechnology trading partnering promotion project group has been formed and actively operated.
An official from the Korea New Drug Development Research Association said, “Through this organizational reorganization, we will strive to further contribute to the development of the Korean pharmaceutical-bio business.” I will do it.”
Copyright © Baby Times Unauthorized reproduction and redistribution prohibited